BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 25750521)

  • 21. Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications.
    Reese M; Dhayat SA
    J Hematol Oncol; 2021 Sep; 14(1):141. PubMed ID: 34496946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigational biomarkers for pancreatic adenocarcinoma: where do we stand?
    Datta J; Vollmer CM
    South Med J; 2014 Apr; 107(4):256-63. PubMed ID: 24937521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
    Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
    Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of microRNA-21 in pancreatic ductal adenocarcinoma: a meta-analysis.
    Hu GY; Tao F; Wang W; Ji KW
    World J Surg Oncol; 2016 Mar; 14():82. PubMed ID: 26969625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters.
    Urayama S
    World J Gastroenterol; 2015 Feb; 21(6):1707-17. PubMed ID: 25684935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
    Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
    PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma.
    Ye Y; Chen J; Zhou Y; Fu Z; Zhou Q; Wang Y; Gao W; Zheng S; Zhao X; Chen T; Chen R
    J Transl Med; 2015 Apr; 13():137. PubMed ID: 25925763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.
    Laeseke PF; Chen R; Jeffrey RB; Brentnall TA; Willmann JK
    Radiology; 2015 Dec; 277(3):644-61. PubMed ID: 26599925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and characterization of the gene expression profiles for protein coding and non-coding RNAs of pancreatic ductal adenocarcinomas.
    Gutiérrez ML; Corchete L; Teodosio C; Sarasquete ME; del Mar Abad M; Iglesias M; Esteban C; Sayagues JM; Orfao A; Muñoz-Bellvis L
    Oncotarget; 2015 Aug; 6(22):19070-86. PubMed ID: 26053098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein.
    Chen J; Wu W; Chen L; Zhou H; Yang R; Hu L; Zhao Y
    Pancreatology; 2013; 13(3):290-7. PubMed ID: 23719603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Detection of Pancreatic Cancer: Opportunities and Challenges.
    Singhi AD; Koay EJ; Chari ST; Maitra A
    Gastroenterology; 2019 May; 156(7):2024-2040. PubMed ID: 30721664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noncoding RNAs in drug-resistant pancreatic cancer: A review.
    Lin Z; Lu S; Xie X; Yi X; Huang H
    Biomed Pharmacother; 2020 Nov; 131():110768. PubMed ID: 33152930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma.
    Chen DT; Davis-Yadley AH; Huang PY; Husain K; Centeno BA; Permuth-Wey J; Pimiento JM; Malafa M
    PLoS One; 2015; 10(8):e0133562. PubMed ID: 26247463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying molecular markers for the early detection of pancreatic neoplasia.
    Goggins M
    Semin Oncol; 2007 Aug; 34(4):303-10. PubMed ID: 17674958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salivary extracellular noncoding RNA: emerging biomarkers for molecular diagnostics.
    Wong DT
    Clin Ther; 2015 Mar; 37(3):540-51. PubMed ID: 25795433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
    Steele CW; Oien KA; McKay CJ; Jamieson NB
    Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of non-coding RNAs in pancreatic cancer: the bane of the microworld.
    Tang YT; Xu XH; Yang XD; Hao J; Cao H; Zhu W; Zhang SY; Cao JP
    World J Gastroenterol; 2014 Jul; 20(28):9405-17. PubMed ID: 25071335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth.
    Schmidt LH; Spieker T; Koschmieder S; Schäffers S; Humberg J; Jungen D; Bulk E; Hascher A; Wittmer D; Marra A; Hillejan L; Wiebe K; Berdel WE; Wiewrodt R; Muller-Tidow C
    J Thorac Oncol; 2011 Dec; 6(12):1984-92. PubMed ID: 22088988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
    Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
    Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.